Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the novel role of ticagrelor to improve long-term LV remodeling following ST-segment elevation myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Collaborators: Chinese PLA General Hospital; Chonnam National University Hospital; Chungbuk National University Hospital; Chungnam National University Hospital; Kyunghee University Medical Center; Kyungpook National University; Kyungpook National University Hospital; National University Heart Centre, Singapore; Pusan National University Yangsan Hospital; Samsung Changwon Hospital; Seoul National University Bundang Hospital; Ulsan University Hospital
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• 18 years and older.

• First-time onset STEMI patients uneventfully treated with primary PCI within 12 hours of onset of symptom.

• Infarct-related artery with TIMI 0, 1, or 2 grade flow at the time of initial diagnostic angiography (before wire passage).

• proximal or mid-portion lesion of epicardial coronary artery.

Exclusion Criteria:

• Previous history of myocardial infarction.

• Left bundle branch block on ECG at the time of screening.

• Cardiogenic shock at the time of randomization.

• Refractory ventricular arrhythmias or atrial fibrillation.

• New York Heart Association class IV congestive heart failure.

• Severe or malignant hypertension (SBP> 180 and/or DBP> 120 mmHg).

• Fibrinolytic therapy.

• History of hemorrhagic stroke.

• Intracranial neoplasm, arteriovenous malformation, or aneurysm.

• Ischemic stroke within 3 months prior to screening.

• Platelet count < 100,000/mm3 or hemoglobin < 10 g/dL.

• A need for oral anticoagulation therapy that cannot be safely discontinued for the duration of the study.

• Women who are known to be pregnant, have given birth within the past 90 days, or are breast-feeding.

• Unable to cooperate with protocol requirements and follow-up procedures.

• A history of P2Y12 receptor inhibitor pretreatment (at least prior 1 month).

• An increased risk of bradycardia.

• Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer.